Catalent’s Strategic Marketing Director, Development and Clinical Services, told Outsourcing-Pharma.com the company’s investments are in part a response to increasing demand for biologics handling.
“We are seeing demand from a mix of existing and new customers, from both large pharma and small biotechs, EU trials and global trials, small molecule and biologics, across all phases,” said Jeremie Trochu.
“Given the increasing mix of biologics in development pipelines, the demand for temperature controlled capabilities throughout the supply chain is increasing. Similarly, with an increasing mix of oncology drugs in clinical trials, the demand for potent handling is increasing.”
Catalent tripled its frozen storage (-18°C) capacity at its facility in Schorndorf, Germany. IT has also added a second automated packaging line for pre-filled syringes, with capabilities for plunger-rod insertion, application of single panel labels, finger flanges, and safety device mounting.
The 60,000 sq ft German site performs contract primary and secondary packaging for oral solids and pre-filled injectables, as well as cold and controlled drug storage; and consulting services for GMP audits.
Catalent also invested in high-potency capabilities at its controlled substances facility in Deeside, UK. The site added a third vault, bringing total controlled substance storage to over 14,000 cubic ft.
Another facility in Bathgate, UK updated its cold storage to include a cryogenic service, suitable for keeping stem cells, regenerative therapies and other clinical materials.
The company also bought two energy-efficient chiller units at its main packaging facility in Bolton, UK. Catalent said their installation will increase output capacity by more than 10%.
The European expansions follow on swiftly from recent investments in Catalent’s US capabilities, including extra temperature-controlled and automated prefilled syringe packaging capacity in Philadelphia, and additional potent handling capacity at Catalent’s site in Kansas City, Missouri.